Potassium%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia. * Prevention of hypokalemia in patients at risk. ## Adult Dosing * **Oral:** * **Treatment of hypokalemia:** Typically 20-100 mEq per day, divided into 2-4 doses. * **Prevention of hypokalemia:** Typically 20-60 mEq per day, divided into 1-2 doses. * Maximum dose is highly individualized based on serum potassium levels and clinical status; doses exceeding 100 mEq/day require careful monitoring. * Sustained-release formulations should be swallowed whole without chewing or crushing. * **Intravenous (IV):** * **Treatment of hypokalemia:** Dosing is based on serum potassium deficit. A common guideline is 10 mEq of KCl will raise serum potassium by approximately 0.1 mEq/L. * **General deficiency:** 20-40 mEq added to 1 L of IV fluid. * **Severe hypokalemia or when rapid correction is needed:** Can be administered at rates up to 10-20 mEq/hour, *but only in a critical care setting with continuous cardiac monitoring*. Doses higher than 20 mEq/hour are rarely used and require extreme caution. * Maximum concentration for peripheral infusion is typically 40 mEq/L; higher concentrations (up to 80 mEq/L) may be used centrally with caution. ## Pediatric Dosing * **Oral:** * **Treatment of hypokalemia:** 2-5 mEq/kg/day, divided into 2-4 doses, not to exceed adult doses. * **Prevention of hypokalemia:** 1-2 mEq/kg/day, divided into 1-2 doses, not to exceed adult doses. * **Intravenous (IV):** * **Treatment of hypokalemia:** Dosing is based on serum potassium deficit. Generally, 0.5-1 mEq/kg per dose is given. * Maximum rate of infusion: 0.5 mEq/kg/hour (or 20 mEq/hour if using older pediatric guidelines), *with continuous cardiac monitoring*. * Maximum concentration for peripheral infusion: 40 mEq/L. ## Dose Adjustments * Renal impairment: Dose reduction is often necessary. Monitor potassium levels closely. In severe renal impairment, potassium administration may be contraindicated. ## Contraindications * Hyperkalemia. * Conditions that may predispose to hyperkalemia (e.g., untreated Addison's disease, severe renal impairment, anuria, oliguria). * Certain gastrointestinal obstructions or motility disorders when using extended-release oral formulations. ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal discomfort. * **Serious:** Hyperkalemia (which can lead to cardiac arrhythmias, muscle weakness, paralysis, and cardiac arrest), gastrointestinal bleeding, ulceration, or perforation (especially with sustained-release oral forms). ## Key Drug Interactions * **Potassium-sparing diuretics (e.g., spironolactone, amiloride):** Increased risk of hyperkalemia. * **ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), NSAIDs:** Can impair potassium excretion, increasing risk of hyperkalemia. * **Digoxin:** Hyperkalemia can increase digoxin toxicity; hypokalemia can potentiate digoxin toxicity. * **Anticholinergics:** May slow GI transit, potentially increasing risk of GI irritation or ulceration with oral KCl. ## Monitoring * Serum potassium levels (frequently, especially during IV administration, dose changes, or in patients with renal impairment). * Renal function (BUN, creatinine). * ECG (especially with rapid IV infusion or history of cardiac issues). * Signs and symptoms of hypokalemia (weakness, fatigue, constipation, arrhythmias) and hyperkalemia (numbness, tingling, muscle weakness, palpitations). ## Clinical Pearls * Oral KCl should be taken with food or immediately after meals to minimize gastrointestinal upset. * Dilute concentrated IV potassium chloride solutions appropriately before administration. * Never administer IV KCl as a direct, undiluted injection. * Sustained-release oral formulations are often preferred for chronic management to improve GI tolerance, but absorption may be variable. *** *This information is intended for healthcare professionals. Always verify current prescribing information and consult with a pharmacist or physician for specific patient management decisions.*